GLP1R and type 2 diabetes mellitus: The 20 articles comprised 14 unique double-blinded RCTs (seven involved the comparison of SGLT2-I with placebo and seven involved the comparison of GLP1-RA) that recruited patients with T2D and reported cardiovascular and/or renal outcomes by race, ethnicity or region (Table 1).